Hormone Therapy for Cancer

Hormone therapy is a systemic cancer treatment that targets the hormonal signals driving tumor growth in specific cancer types. This page covers the biological mechanisms behind hormonal manipulation, the cancer types most commonly treated with this approach, and the clinical and regulatory boundaries that guide its use. Understanding how hormone therapy differs from chemotherapy and immunotherapy helps clarify where it fits within broader oncology treatment planning.

Definition and scope

Hormone therapy — also called endocrine therapy or hormonal therapy — refers to treatments that reduce the body's production of certain hormones or block their ability to bind to cancer cells. It is distinct from hormone replacement therapy used in non-oncologic contexts. The U.S. Food and Drug Administration (FDA) has approved hormone therapy agents across multiple cancer categories, with the largest approved indication groups being hormone receptor-positive (HR+) breast cancer and castration-sensitive or castration-resistant prostate cancer.

The scope of hormone therapy is defined by receptor status: tumors that express estrogen receptors (ER), progesterone receptors (PR), or androgen receptors (AR) are candidates for hormonal manipulation. Tumors lacking these receptors do not respond to this class of treatment. According to the National Cancer Institute (NCI), approximately 70–80% of breast cancers are hormone receptor-positive, making endocrine therapy the most widely applicable systemic treatment in that disease category.

Hormone therapy is classified under the broader regulatory context for oncology framework governing drug approvals, clinical trial requirements, and post-market surveillance obligations established by the FDA under 21 C.F.R. Part 312 and related provisions.

How it works

Hormonal therapies act through 4 primary mechanisms, depending on the agent class:

  1. Receptor blockade — Selective estrogen receptor modulators (SERMs) such as tamoxifen bind competitively to estrogen receptors on tumor cells, preventing estrogen from activating gene transcription that promotes cell proliferation.
  2. Receptor degradation — Selective estrogen receptor degraders (SERDs) such as fulvestrant bind to and mark the ER protein for cellular degradation, reducing receptor concentration rather than simply occupying it.
  3. Hormone synthesis inhibition — Aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane suppress the enzyme aromatase, which converts androgens to estrogens in peripheral tissues. AIs reduce circulating estrogen levels by more than 95% in postmenopausal women (NCI Drug Dictionary).
  4. Androgen deprivation — In prostate cancer, luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide suppress testicular testosterone production, a strategy termed androgen deprivation therapy (ADT). Androgen receptor antagonists such as enzalutamide block AR signaling directly at the receptor level.

The National Comprehensive Cancer Network (NCCN) publishes evidence-based clinical practice guidelines stratifying these mechanisms by disease subtype, receptor status, menopausal status, and prior treatment history.

Common scenarios

Hormone therapy is deployed across several cancer types and clinical contexts:

Breast cancer (HR+/HER2-): Adjuvant tamoxifen is administered for 5–10 years in premenopausal women with early-stage HR+ disease. Postmenopausal women are typically offered AIs as first-line adjuvant therapy. In metastatic settings, endocrine therapy combined with CDK4/6 inhibitors represents a standard first-line approach for HR+/HER2- disease, per NCCN Guidelines for Breast Cancer.

Prostate cancer: ADT is used across castration-sensitive, biochemically recurrent, locally advanced, and metastatic prostate cancer settings. The timing and duration of ADT vary by disease stage. Second-generation AR-targeted agents are approved for metastatic castration-resistant prostate cancer (mCRPC).

Endometrial cancer: Progestin-based therapy (e.g., megestrol acetate) is used in select cases of hormone receptor-positive endometrial carcinoma, particularly in patients who are not surgical candidates, as noted in NCI treatment summaries.

Ovarian and other cancers: Hormone therapy has a more limited but defined role in granulosa cell tumors and select cases of ovarian cancer with hormone receptor expression.

Hormone therapy may be used as neoadjuvant therapy (before surgery), adjuvant therapy (after definitive local treatment), or as primary systemic therapy in metastatic disease. Its role as a stand-alone treatment or in combination with targeted agents, immunotherapy, or chemotherapy depends on molecular profiling results.

Decision boundaries

The decision to use hormone therapy is governed by 4 principal clinical parameters:

  1. Receptor status — Confirmed ER, PR, or AR positivity on pathology is a prerequisite. Testing is standardized under College of American Pathologists (CAP) and American Society of Clinical Oncology (ASCO) joint guideline requirements for HER2 and hormone receptor testing.
  2. Menopausal status — Determines which agent class is appropriate; AIs are contraindicated as monotherapy in premenopausal women without concurrent ovarian suppression because residual ovarian estrogen production would render AI therapy inadequate.
  3. Disease stage and burden — Visceral crisis or rapidly progressive metastatic disease may favor chemotherapy over endocrine therapy despite HR positivity, per NCCN criteria.
  4. Prior endocrine therapy exposure — Resistance patterns (primary vs. acquired endocrine resistance) influence sequencing; ESR1 mutation testing via liquid biopsy guides selection of later-line SERDs in breast cancer.

Hormone therapy carries defined safety risks managed within oncology practice: bone density loss from estrogen suppression (monitored under ASCO/ASBMR guidelines), thromboembolic risk with tamoxifen, hot flashes and sexual dysfunction, and cardiovascular risks associated with long-term ADT in prostate cancer. These fall within safety monitoring frameworks established by the FDA's MedWatch program and institutional risk evaluation and mitigation strategies (REMS) where applicable.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)